Supernus Pharmaceuticals, Inc. logo SUPN - Supernus Pharmaceuticals, Inc.

Price: -- -- | CONSENSUS: Buy DETAILS
STRONG
BUY 0
BUY 9
HOLD 5
SELL 0
STRONG
SELL 0
| PRICE TARGET: $57.60 DETAILS
HIGH: $65.00
LOW: $40.00
MEDIAN: $63.00
CONSENSUS: $57.60
UPSIDE: 30.29%

Stock News

Chloe Kim Teams Up with Qelbree®, the #1 Prescribed Branded Non-Stimulant ADHD Treatment*, to Help Empower People Navigating ADHD

Chloe Kim Teams Up with Qelbree®, the #1 Prescribed Branded Non-Stimulant ADHD Treatment*, to Help Empower People Navigating ADHD

ROCKVILLE, Md., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Professional snowboarder, Chloe Kim, is partnering with Supernus Pharmaceuticals as a compensated ambassador to discuss her journey with attention-deficit/hyperactivity disorder (ADHD) and her treatment plan with Qelbree (viloxazine extended-release capsules), a once-daily, non-stimulant medication for patients 6 years and older. Designed for flexible once-a-day routine integration, Qelbree offers 24-hour medication exposure, no evidence of abuse potential, and versatile administration options, including the ability to be sprinkled and taken at any time of day (either morning or night). Through this partnership, Chloe Kim will open up about her own diagnosis to challenge misconceptions about ADHD. By sharing her lived experience, she will encourage others to advocate for their health and initiate collaborative conversations with their doctors about a potential treatment plan.

Aug 31, 2026 04:30 AM • globenewswire.com
SUPN Stock Alert: Halper Sadeh LLC is Investigating Whether Supernus Pharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholders

SUPN Stock Alert: Halper Sadeh LLC is Investigating Whether Supernus Pharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholders

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the sale of Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) to Indivior Pharmaceuticals, Inc. for 1.5401 common shares of Indivior for each share of Supernus.Halper Sadeh encourages Supernus shareholders to click here to learn more about their rights and options or contact Daniel Sadeh or Zachary Halper free of charge at (212) 763-0060 or [email protected] or [email protected] investigation con.

Aug 29, 2026 03:13 AM • businesswire.com
BlackRock Inc. Purchases New Position in Supernus Pharmaceuticals, Inc. $SUPN

BlackRock Inc. Purchases New Position in Supernus Pharmaceuticals, Inc. $SUPN

BlackRock Inc. purchased a new position in Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) in the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 9,350,046 shares of the specialty pharmaceutical company's stock, valued at approximately $434,871,000. BlackRock Inc. owned approximately 16.08% of

Aug 26, 2026 01:39 AM • defenseworld.net
Critical Survey: Vectura Group (OTCMKTS:VEGPF) versus Supernus Pharmaceuticals (NASDAQ:SUPN)

Critical Survey: Vectura Group (OTCMKTS:VEGPF) versus Supernus Pharmaceuticals (NASDAQ:SUPN)

Supernus Pharmaceuticals (NASDAQ: SUPN - Get Free Report) and Vectura Group (OTCMKTS:VEGPF - Get Free Report) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, profitability, earnings, analyst recommendations, risk and institutional ownership. Risk and Volatility Supernus Pharmaceuticals has a beta

Aug 23, 2026 11:59 PM • defenseworld.net
Supernus Pharmaceuticals, Inc. $SUPN Shares Sold by Assenagon Asset Management S.A.

Supernus Pharmaceuticals, Inc. $SUPN Shares Sold by Assenagon Asset Management S.A.

Assenagon Asset Management S.A. lessened its holdings in Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) by 86.2% in the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 73,175 shares of the specialty pharmaceutical company's stock after selling 457,443 shares during the

Aug 12, 2026 11:38 PM • defenseworld.net
California State Teachers Retirement System Grows Stock Holdings in Supernus Pharmaceuticals, Inc. $SUPN

California State Teachers Retirement System Grows Stock Holdings in Supernus Pharmaceuticals, Inc. $SUPN

California State Teachers Retirement System lifted its stake in Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) by 26.9% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 67,686 shares of the specialty pharmaceutical company's stock after purchasing an additional 14,347

Aug 08, 2026 11:46 PM • defenseworld.net
Supernus Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Supernus Pharmaceuticals, Inc. - SUPN

Supernus Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Supernus Pharmaceuticals, Inc. - SUPN

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Supernus Pharmaceuticals, Inc. (NasdaqGM: SUPN) to Indivior Pharmaceuticals, Inc. (Nasdaq: INDV). Under the terms of the proposed transaction, shareholders of Supernus will receive 1.5401 common shares of Indivior for each share of Supernus that they own. KSF is seeking to determine whether this con.

Aug 07, 2026 07:21 AM • businesswire.com (Hide legal announcements)

Price Targets